{ "schemaVersion": "deck-intelligence.v1", "id": "019dd923-622c-750b-8b9d-0fffb58e3a0f", "slug": "9b4a362a0151", "title": "Bristol-Myers Squibb Company (BMY)", "subtitle": "Jeffrey C. Smith · 2019-02", "author": "Jeffrey C. Smith", "date": "2019-02-28 00:00:00", "pageCount": 16, "kind": "shareholder-letter", "orientation": "portrait", "aspectRatio": 0.77272725, "targetCompany": "Bristol-Myers Squibb Company", "targetTicker": "BMY", "document": { "id": "019dd923-622c-750b-8b9d-0fffb58e3a0f", "slug": "9b4a362a0151", "title": "Bristol-Myers Squibb Company (BMY)", "rawTitle": "ex1todfan14a06297263 022819", "authorId": "03_Starboard_Value", "authorName": "Jeffrey C. Smith", "authorDisplay": "Jeffrey C. Smith", "kind": { "slug": "shareholder-letter", "label": "Shareholder letter" }, "sourceType": { "slug": "activist_investor", "label": "Activist investor" }, "fileName": "2019-02-ex1todfan14a06297263_022819.pdf", "sourceUrl": null, "sourceDate": null, "presentationDate": "2019-02-28 00:00:00", "ingestedAt": "2026-04-23 07:52:13+00", "status": "ready", "pageCount": 16, "orientation": "portrait", "aspectRatio": 0.77272725, "targetCompany": "Bristol-Myers Squibb Company", "targetTicker": "BMY", "metadata": { "local_root": "/tmp/legacy-images/9b4a362a0151", "activist_firm": "Starboard Value LP", "origin_corpus": "contrarian", "extraction_seconds": 227.08846735954285 } }, "coverage": { "pageCount": 16, "pagesIndexed": 5, "pagesWithImages": 5, "pagesWithMetadata": 5, "imageCoveragePct": 31.3, "metadataCoveragePct": 31.3, "componentCount": 33, "chartCount": 5, "metricSlides": 0, "toolMatches": 3, "documentToolMatches": 3, "frameworkMatches": 6, "arcMatches": 1, "beatMatches": 3, "loopMatches": 2, "patternMatches": 0, "storymakersMatch": false, "scoreAvailable": false, "reviewAvailable": false, "activistThesisAvailable": true, "pitchdeckMetadataAvailable": false, "pitchdeckProfileAvailable": false }, "blocks": [], "matches": { "arcs": [ { "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "matchId": "b3a3f81d-4c4c-427b-9370-7740b99af9bf", "evidence": "The document follows a problem-agitate-solution narrative, highlighting the underperformance, questioning R&D productivity, and providing a solution to improve it.", "isPrimary": true, "confidence": 0.8, "extraction": { "at": "2026-07-16 22:03:56.744827+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "beats": [ { "to": 2, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 2, "name": "Problem", "beatId": "b1777d52-1b65-4d01-8339-b4d49bc93da2", "matchId": "b3a3f81d-4c4c-427b-9370-7740b99af9bf", "beatType": { "name": "Problem (Identify pain)", "slug": "problem-agitate-solution-problem-identify-pain", "status": "active", "canonId": "019dd9b8-0e78-74bb-b8f6-54348367a131", "version": 1, "description": null }, "evidence": "The document starts by highlighting the underperformance of Bristol-Myers Share Price", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 9, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 7, "name": "Agitate", "beatId": "b2d08d86-8e4d-47b4-8dc5-26870b4df100", "matchId": "b3a3f81d-4c4c-427b-9370-7740b99af9bf", "beatType": { "name": "Agitate (Make it worse)", "slug": "problem-agitate-solution-agitate-make-it-worse", "status": "active", "canonId": "019dd9b8-0f5a-71dd-bae7-8fadb0d09456", "version": 1, "description": null }, "evidence": "The document then questions the company's R&D productivity", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Development", "slug": "development", "status": "active", "canonId": "019dd9b8-0332-7008-b3aa-11b0840a57b1", "version": 1, "description": "The middle stretch in arcs that have one. Often where length problems creep in." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 13, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 13, "name": "Solution", "beatId": "69150cef-b68a-4ac9-9ada-bbc434fbe962", "matchId": "b3a3f81d-4c4c-427b-9370-7740b99af9bf", "beatType": { "name": "Solution (Provide relief)", "slug": "problem-agitate-solution-solution-provide-relief", "status": "active", "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd", "version": 1, "description": null }, "evidence": "The document provides a solution to improve R&D productivity", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 9, "from": 2, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null, "categoryName": "Urgency", "categorySlug": "urgency" }, "matchId": "9478efc2-9f01-4b02-a15d-2d6af84ca74a", "evidence": "The document highlights the underperformance and questions R&D productivity, implying a cost of inaction", "position": 0, "objective": "to highlight the cost of not improving R&D productivity", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:03:56.892514+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 13, "from": 13, "loop": { "name": "51_voice_of_customer", "slug": "51-voice-of-customer", "status": "active", "bestFor": "Product strategy, customer experience, market research", "canonId": "019dd956-7aaf-750b-950b-af0df38f5266", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "What Customers Say (Verbatim) -> The Pattern Across Voices -> The Insight -> The Response", "description": "Let customer quotes and feedback drive the narrative and validate the insight", "familyLabel": null, "categoryName": "Validation", "categorySlug": "validation" }, "matchId": "996cc727-a228-47d1-8c7f-e4954377a0d3", "evidence": "The document provides select management commentary on R&D productivity", "position": 1, "objective": "to provide a solution that addresses shareholder concerns", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:03:56.928365+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "tools": [ { "tool": { "name": "CEO quote contradiction", "slug": "ceo-quote-contradiction", "status": "active", "bestFor": "When management credibility is the lever", "canonId": "019dd9e1-52e9-717f-8454-93e627563ed6", "version": 1, "bodyDocId": "019dd9a1-8296-720d-8f51-da76937f9415", "description": "You reproduce management's own words — verbatim, with source and date — and\nthen place them next to the outcome that contradicts them. The CEO built\nthe rope; you put it around their own neck.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "document", "agents": null, "matchId": "8d602dcc-cc9d-4b5e-90e1-2f08013ad21b", "evidence": null, "pageRefs": null, "priority": null, "whenToUse": "When management credibility is the lever", "confidence": null, "extraction": { "at": "2026-04-29 12:07:50.209813+00", "model": "unknown-legacy", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": null, "whyItWorks": "- **Maximum credibility**: no adjective you could write is as damning as the\n target's own prior statement.\n- **No rebuttal path**: management can't argue they didn't say it.\n- **It forces accountability onto a person**, not an institution — even if\n you aren't explicitly naming a villain elsewhere.\n- **Reporters amplify it**. A CEO-quote-contradiction slide is quotable,\n which means it lands in WSJ/FT/Bloomberg coverage.", "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Peer gap chart", "slug": "peer-gap", "status": "active", "bestFor": "When relative underperformance is the core argument", "canonId": "019dd9e1-54f1-775a-94a1-d5cf3bb75abf", "version": 1, "bodyDocId": "019dd9a1-8653-7748-9050-807f067196c3", "description": "A single visual that benchmarks the target against its best-in-class peers on\na single quantitative KPI — and shows the target losing. The gap is the\npunchline.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "document", "agents": null, "matchId": "053107a8-c777-4bb8-8f09-8d7812b0a72f", "evidence": null, "pageRefs": null, "priority": null, "whenToUse": "When relative underperformance is the core argument", "confidence": null, "extraction": { "at": "2026-04-29 12:07:50.209813+00", "model": "unknown-legacy", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": null, "whyItWorks": "- It's the **most credible claim in the deck** because it's arithmetic, not\n opinion.\n- It's immediately **actionable** — close this gap and value accrues.\n- It **pre-empts the \"context is different\" defence** by pitting the target\n against direct peers in the same category.", "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Villain naming", "slug": "villain-naming", "status": "active", "bestFor": "When governance or specific decisions are the core thesis", "canonId": "019dd9e1-55a4-74db-9314-0ced4cd46cd2", "version": 1, "bodyDocId": "019dd9a1-88f1-72ad-8f4e-56ec29d7b369", "description": "You identify a **specific person** responsible for the target's underperformance\nor the behaviour you want changed — and name them. Not \"management\" or \"the\nboard\". A named executive or director with a specific failure attributable to\nthem.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "document", "agents": null, "matchId": "1b900449-33c0-4474-87c8-dd168a3950f6", "evidence": "Giovanni Caforio (Chairman & CEO, Bristol-Myers Squibb); Celgene management (Mark Alles, Patrick Flanigan, Scott Smith, Peter Kellogg, Nadim Ahmed, Jay Backstrom) whose pipeline projections are contradicted by quoted record", "pageRefs": null, "priority": null, "whenToUse": "When governance or specific decisions are the core thesis", "confidence": null, "extraction": { "at": "2026-04-29 12:07:50.209813+00", "model": "unknown-legacy", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": null, "whyItWorks": "- **Accountability needs a face.** Voters (shareholders, regulators,\n journalists) act faster against people than institutions.\n- **Credibility rises with specificity.** \"The CFO has repeatedly missed\n guidance\" > \"Management has missed guidance\".\n- It **pre-empts evasion**. An individual can be removed; an abstraction\n cannot.\n- It **forces the target to respond personally** — and their defensive\n response usually generates more attention for your thesis.", "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [ { "matchId": "d73fef59-6d99-4ced-839e-b890308403b0", "evidence": "Table comparing performance metrics against peers and indices", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 21:01:15.931+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 2, "frameworkName": "comparison_frame" }, { "matchId": "0624b94c-427f-4d55-adc7-f78526c2de81", "evidence": "Comparing historical drug revenue concentration with future pipeline revenue uncertainty.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 21:01:14.521+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 7, "frameworkName": "comparison_frame" }, { "matchId": "46bb7d83-e9b0-4059-9f1d-1bf78dca2ac3", "evidence": "Contrasts past management quotes with subsequent negative outcomes (termination/RTF).", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 21:01:14.064+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 8, "frameworkName": "ceo-quote-contradiction" }, { "matchId": "8ed2b16b-5c76-4fde-ab06-babd12451c0b", "evidence": "Contrasting past optimistic quotes with later, more measured statements.", "framework": null, "confidence": 0.95, "extraction": { "at": "2026-05-02 21:01:17.859+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 9, "frameworkName": "ceo-quote-contradiction" }, { "matchId": "71b7bb2e-d227-4dcb-9338-c047141878a9", "evidence": "Visual representation of management quotes over time.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 21:01:17.859+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 9, "frameworkName": "timeline" }, { "matchId": "0eb9bb6c-81ee-483a-8abf-77083f7fd13b", "evidence": "Contrasting optimistic CEO quotes with negative stock performance data.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 21:01:17.731+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 13, "frameworkName": "ceo-quote-contradiction" } ], "patterns": [] }, "storymakers": null, "score": null, "review": null, "activistThesis": { "tone": "adversarial", "notes": "16-page shareholder letter filed as proxy solicitation exhibit (EX1 to DFAN14A) opposing BMY's January 2019 agreement to acquire Celgene for ~$91bn. Hybrid format: letter prose with ~15 institutional charts and CEO-quote callout boxes interspersed — not a true deck but denser than a plain letter. Signed Feb 28, 2019 by Jeffrey C. Smith, Managing Member. Ahead of April 12, 2019 Special Meeting share-issuance vote. Standout rhetorical moves: (i) patent-cliff framing — REVLIMID at 63% of Celgene revenue is unprecedented vs peer blockbusters (11-33%); (ii) serial CEO-quote contradictions on GED-0301, ozanimod, and JCAR017 timelines (pp. 8-9); (iii) annotated stock chart (p.11) tying first-activist/second-activist involvement to the 'defensive' merger decision. Stake size not disclosed in this filing. No sum-of-parts; valuation argument is peer multiple discount (BMY now 2.7x below peers vs 19.8x premium in 2015). campaign_phase set to initial_thesis — this is the first public articulation of the thesis, though the letter simultaneously announces the proxy solicitation. Wellington Management publicly opposed the deal around the same time — Starboard positions itself alongside 'numerous other large, long-term shareholders'.", "kpisCited": [ { "detail": "BMY underperformance of (36.7%) over 3Y; (42.0%) over 5Y; (60.9%) over 10Y", "metric": "3-Year TSR vs S-4 Peer Group" }, { "detail": "BMY (11.9%) vs peer group +17.5%, underperformance of (29.4%); (41.5%) vs S&P 500", "metric": "TSR during Caforio tenure as CEO" }, { "detail": "63% — vs 11-33% for comparable blockbusters (SINGULAIR, LIPITOR, CRESTOR, CYMBALTA, PLAVIX)", "metric": "REVLIMID share of Celgene revenue at LOE" }, { "detail": "~90% / ~$17bn must come from yet-unlaunched products (base case of ~$19bn)", "metric": "Share of 2028 Celgene revenue from un-commercialized pipeline" }, { "detail": "92% of Phase I studies fail — only 2-3 of ~20 early-stage Celgene assets likely to be approved", "metric": "Phase I FDA approval rate (per BMY 10-K)" }, { "detail": "BMY 30% vs 17% peer average — highest in the peer group", "metric": "R&D as % of revenue (5-year average)" }, { "detail": "BMY 32% vs 38% peer average", "metric": "FY2018 EBITDA margin" }, { "detail": "Compressed from 19.8x premium in 2015 to (2.7x) discount currently", "metric": "NTM P/E multiple premium vs peers" }, { "detail": "Only ~2 weeks to diligence ~30 highly technical pipeline products", "metric": "Full data room access pre-announcement" }, { "detail": "$22bn spent with no new major drug brought to market", "metric": "Celgene cumulative R&D spend since last major drug launch (2014)" }, { "detail": "$7.3bn spread between minimum and maximum cumulative estimates", "metric": "Wall Street 2028 revenue range for Celgene's 5 near-term pipeline launches" }, { "detail": "BMY +13% vs peers +52% vs S&P 500 +55% — ~42% underperformance", "metric": "5-Year share price performance (Jan 2014 – Jan 2019)" } ], "closingAsk": "Vote down the ill-advised Celgene share issuance at the April 12 Special Meeting and support Starboard's slate of director nominees at the 2019 Annual Meeting.", "extraction": { "at": "2026-04-23 07:52:13+00", "model": "unknown-legacy", "runId": null, "seconds": 227.08847, "promptVersion": null }, "scqaReward": "A better path — margin expansion toward the 38% peer average, targeted tuck-ins, or a sale of BMY as a premier oncology asset at a strategic premium — could unlock substantial value versus the risk-laden Celgene deal.", "thesisTypes": [ "strategic_pivot", "governance_board", "sale_of_company", "operational_turnaround" ], "top3Reasons": [ "BMY is buying pharma's largest-ever patent cliff: REVLIMID is 63% of Celgene revenue and faces generics from 2022", "Celgene pipeline must replace >90% of revenue by 2028, relying on repeatedly-missed CAR-T and ozanimod assumptions", "Two-week full data room rushed a 'bet the company' deal while no BMY sale process was ever explored" ], "scqaSituation": "Bristol-Myers Squibb is a leading immuno-oncology pharmaceutical company whose shares have underperformed S&P 500 peers by roughly 37% over three years under CEO Giovanni Caforio, amid repeated OPDIVO clinical-trial setbacks.", "thesisSummary": "Starboard opposes Bristol-Myers Squibb's proposed $91 billion acquisition of Celgene, arguing that BMY — already underperforming peers by nearly 37% over three years under CEO Giovanni Caforio — is pursuing a 'bet the company' deal to acquire one of pharma's largest-ever patent cliffs. Celgene's REVLIMID generates 63% of revenues and faces generic competition beginning 2022, while BMY management's base case requires Celgene's unproven pipeline to replace over $17 billion of revenue by 2028 through optimistic CAR-T and ozanimod assumptions management itself has already walked back. With only two weeks of full data room access and no exploration of alternatives, the process appears defensive. Starboard will solicit votes against the share issuance at the April 12 Special Meeting and has nominated directors to hold the Board accountable and pursue a standalone path, tuck-ins, or a sale of BMY at a premium.", "primaryDemands": [ "Vote against the share issuance proposal for the Celgene acquisition at the April 12, 2019 Special Meeting", "Elect Starboard's nominated slate of director candidates at the 2019 Annual Meeting", "Explore all strategic alternatives including a standalone plan with margin improvement, targeted tuck-ins, or a sale of the Company at a premium", "Provide books and records under Delaware law regarding the diligence process leading to the Celgene deal" ], "scqaResolution": "Starboard will solicit shareholders to vote down the share issuance at the April 12 Special Meeting and has nominated a slate of directors for the 2019 Annual Meeting to hold the Board accountable and pursue alternatives.", "thesisOneLiner": "Bristol-Myers' $91bn Celgene acquisition buys pharma's largest patent cliff; Starboard urges shareholders to vote it down and replace directors to pursue a standalone plan or sale.", "precedentsCited": [], "scqaComplication": "Rather than fixing its own strategy, BMY is pursuing a $91bn 'bet the company' acquisition of Celgene, inheriting a massive REVLIMID-driven patent cliff and banking on an unproven pipeline to replace over 60% of Celgene revenue.", "narrativeInterest": 4, "notableSlidePages": [ 2, 7, 8, 9, 13 ], "peerCompaniesCited": [ "ABBV", "AGN", "AMGN", "AZN", "BIIB", "LLY", "GILD", "GSK", "JNJ", "MRK", "NOVN", "NOVO", "PFE", "ROG", "SAN", "CELG" ], "valuationFrameworks": [ "multiple_comparison" ], "visualCraftInterest": 3 }, "pitchdeck": { "metadata": null, "profile": null }, "slides": [ { "page": 1, "type": "setup", "block": null, "metadata": { "slideType": null, "slideTypeCanon": null, "function": null, "functionCanon": null, "density": null, "densityScore": null, "componentCount": null, "textChars": null, "nDataPoints": null, "notes": null, "elementsJson": null, "confidence": null, "extraction": { "model": null, "runId": null, "at": null, "seconds": null, "promptVersion": null } }, "links": { "slide": "/slides/019dd923-622c-750b-8b9d-0fffb58e3a0f/1", "deck": "/decks/019dd923-622c-750b-8b9d-0fffb58e3a0f", "deckAnchor": "/decks/019dd923-622c-750b-8b9d-0fffb58e3a0f#slide-1", "deckJson": "/decks/019dd923-622c-750b-8b9d-0fffb58e3a0f.json" }, "components": [], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [] }, { "page": 2, "type": "analysis", "title": "The slide uses quantitative underperformance data to justify an activist campaign against a merger.", "function": "expose_gap", "rawType": "peer_gap", "block": null, "metadata": { "slideType": "peer_gap", "slideTypeCanon": { "name": "Peer gap", "slug": "peer_gap", "status": "active", "canonId": "019de52d-10e5-74bd-8325-9f49c945a0aa", "version": 1, "description": null }, "function": "expose_gap", "functionCanon": { "name": "Expose gap", "slug": "expose_gap", "status": "active", "canonId": "019de52d-1795-772d-8f3a-75ccfb93fe58", "version": 1, "description": null }, "density": "dense", "densityScore": 55, "componentCount": 6, "textChars": 757, "nDataPoints": 30, "notes": "The slide uses quantitative underperformance data to justify an activist campaign against a merger.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 21:01:15.931+00", "seconds": 6.597, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-622c-750b-8b9d-0fffb58e3a0f/2", "deck": "/decks/019dd923-622c-750b-8b9d-0fffb58e3a0f", "deckAnchor": "/decks/019dd923-622c-750b-8b9d-0fffb58e3a0f#slide-2", "deckJson": "/decks/019dd923-622c-750b-8b9d-0fffb58e3a0f.json" }, "components": [ { "bbox": { "h": 0.085, "w": 0.764, "x": 0.118, "y": 0.765 }, "kind": "list", "text": "1) Bristol-Myers is buying a company with a massive patent cliff - among the largest in pharmaceutical industry history.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Numbered list", "slug": "numbered", "status": "active", "canonId": "019de52c-fcc0-7718-a284-a4250c805df2", "version": 1, "description": null }, "framework": null }, "subkind": "numbered", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 21:01:15.931+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0cf78031-a760-41e2-95fd-67a195c59634", "parentComponentId": null }, { "bbox": { "h": 0.065, "w": 0.764, "x": 0.118, "y": 0.495 }, "kind": "paragraph", "text": "The actions we are taking – specifically, our intent to solicit shareholders to block the proposed acquisition of Celgene – are not taken lightly.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 21:01:15.931+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "195d014e-4b0b-45e4-b6e1-8e3c1638af36", "parentComponentId": null }, { "bbox": { "h": 0.095, "w": 0.764, "x": 0.118, "y": 0.605 }, "kind": "paragraph", "text": "We have rigorously studied the proposed transaction since its announcement in early January in order to better understand the perspectives of all parties involved.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 21:01:15.931+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "22150527-b775-4c8b-8116-1359dfb49e5e", "parentComponentId": null }, { "bbox": { "h": 0.065, "w": 0.764, "x": 0.118, "y": 0.375 }, "kind": "paragraph", "text": "These results are not reflective of a management team and Board of Directors that has earned the right, in our view, to execute on a “bet the company” acquisition.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 21:01:15.931+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "948691a5-3f90-4434-a034-fc3b5a7b7ca3", "parentComponentId": null }, { "bbox": { "h": 0.185, "w": 0.764, "x": 0.118, "y": 0.125 }, "kind": "table", "text": "Total Shareholder Return table comparing BMS to S&P 500, IBB, and S-4 Peer Group over 1, 3, 5, 10 years and Caforio Tenure.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 21:01:15.931+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3f4a1dea-cedf-4375-8305-af0786ea094a", "parentComponentId": null }, { "bbox": { "h": 0.025, "w": 0.764, "x": 0.118, "y": 0.098 }, "kind": "title", "text": "Bristol-Myers Share Price Underperformance", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 21:01:15.931+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "89c4989a-1373-4340-8a9a-a5c2f72138ce", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "d73fef59-6d99-4ced-839e-b890308403b0", "evidence": "Table comparing performance metrics against peers and indices", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 21:01:15.931+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 2, "frameworkName": "comparison_frame" } ], "arcBeats": [ { "to": 2, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 2, "name": "Problem", "beatId": "b1777d52-1b65-4d01-8339-b4d49bc93da2", "matchId": "b3a3f81d-4c4c-427b-9370-7740b99af9bf", "beatType": { "name": "Problem (Identify pain)", "slug": "problem-agitate-solution-problem-identify-pain", "status": "active", "canonId": "019dd9b8-0e78-74bb-b8f6-54348367a131", "version": 1, "description": null }, "evidence": "The document starts by highlighting the underperformance of Bristol-Myers Share Price", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 9, "from": 2, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "9478efc2-9f01-4b02-a15d-2d6af84ca74a", "evidence": "The document highlights the underperformance and questions R&D productivity, implying a cost of inaction", "position": 0, "objective": "to highlight the cost of not improving R&D productivity", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:03:56.892514+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 3, "type": "setup", "block": null, "metadata": { "slideType": null, "slideTypeCanon": null, "function": null, "functionCanon": null, "density": null, "densityScore": null, "componentCount": null, "textChars": null, "nDataPoints": null, "notes": null, "elementsJson": null, "confidence": null, "extraction": { "model": null, "runId": null, "at": null, "seconds": null, "promptVersion": null } }, "links": { "slide": "/slides/019dd923-622c-750b-8b9d-0fffb58e3a0f/3", "deck": "/decks/019dd923-622c-750b-8b9d-0fffb58e3a0f", "deckAnchor": "/decks/019dd923-622c-750b-8b9d-0fffb58e3a0f#slide-3", "deckJson": "/decks/019dd923-622c-750b-8b9d-0fffb58e3a0f.json" }, "components": [], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 9, "from": 2, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "9478efc2-9f01-4b02-a15d-2d6af84ca74a", "evidence": "The document highlights the underperformance and questions R&D productivity, implying a cost of inaction", "position": 0, "objective": "to highlight the cost of not improving R&D productivity", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:03:56.892514+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 4, "type": "setup", "block": null, "metadata": { "slideType": null, "slideTypeCanon": null, "function": null, "functionCanon": null, "density": null, "densityScore": null, "componentCount": null, "textChars": null, "nDataPoints": null, "notes": null, "elementsJson": null, "confidence": null, "extraction": { "model": null, "runId": null, "at": null, "seconds": null, "promptVersion": null } }, "links": { "slide": "/slides/019dd923-622c-750b-8b9d-0fffb58e3a0f/4", "deck": "/decks/019dd923-622c-750b-8b9d-0fffb58e3a0f", "deckAnchor": "/decks/019dd923-622c-750b-8b9d-0fffb58e3a0f#slide-4", "deckJson": "/decks/019dd923-622c-750b-8b9d-0fffb58e3a0f.json" }, "components": [], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 9, "from": 2, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "9478efc2-9f01-4b02-a15d-2d6af84ca74a", "evidence": "The document highlights the underperformance and questions R&D productivity, implying a cost of inaction", "position": 0, "objective": "to highlight the cost of not improving R&D productivity", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:03:56.892514+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 5, "type": "setup", "block": null, "metadata": { "slideType": null, "slideTypeCanon": null, "function": null, "functionCanon": null, "density": null, "densityScore": null, "componentCount": null, "textChars": null, "nDataPoints": null, "notes": null, "elementsJson": null, "confidence": null, "extraction": { "model": null, "runId": null, "at": null, "seconds": null, "promptVersion": null } }, "links": { "slide": "/slides/019dd923-622c-750b-8b9d-0fffb58e3a0f/5", "deck": "/decks/019dd923-622c-750b-8b9d-0fffb58e3a0f", "deckAnchor": "/decks/019dd923-622c-750b-8b9d-0fffb58e3a0f#slide-5", "deckJson": "/decks/019dd923-622c-750b-8b9d-0fffb58e3a0f.json" }, "components": [], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 9, "from": 2, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "9478efc2-9f01-4b02-a15d-2d6af84ca74a", "evidence": "The document highlights the underperformance and questions R&D productivity, implying a cost of inaction", "position": 0, "objective": "to highlight the cost of not improving R&D productivity", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:03:56.892514+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 6, "type": "setup", "block": null, "metadata": { "slideType": null, "slideTypeCanon": null, "function": null, "functionCanon": null, "density": null, "densityScore": null, "componentCount": null, "textChars": null, "nDataPoints": null, "notes": null, "elementsJson": null, "confidence": null, "extraction": { "model": null, "runId": null, "at": null, "seconds": null, "promptVersion": null } }, "links": { "slide": "/slides/019dd923-622c-750b-8b9d-0fffb58e3a0f/6", "deck": "/decks/019dd923-622c-750b-8b9d-0fffb58e3a0f", "deckAnchor": "/decks/019dd923-622c-750b-8b9d-0fffb58e3a0f#slide-6", "deckJson": "/decks/019dd923-622c-750b-8b9d-0fffb58e3a0f.json" }, "components": [], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 9, "from": 2, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "9478efc2-9f01-4b02-a15d-2d6af84ca74a", "evidence": "The document highlights the underperformance and questions R&D productivity, implying a cost of inaction", "position": 0, "objective": "to highlight the cost of not improving R&D productivity", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:03:56.892514+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 7, "type": "tension", "title": "The slide uses a combination of a bar chart for historical revenue concentration and a floating bar chart (range) for analyst revenue estimates.", "function": "expose_gap", "rawType": "peer_benchmark", "block": null, "metadata": { "slideType": "peer_benchmark", "slideTypeCanon": { "name": "Peer benchmark", "slug": "peer_benchmark", "status": "active", "canonId": "019de52d-08f0-7158-a78d-d7b5331fefaf", "version": 1, "description": null }, "function": "expose_gap", "functionCanon": { "name": "Expose gap", "slug": "expose_gap", "status": "active", "canonId": "019de52d-1795-772d-8f3a-75ccfb93fe58", "version": 1, "description": null }, "density": "dense", "densityScore": 71, "componentCount": 7, "textChars": 1279, "nDataPoints": 16, "notes": "The slide uses a combination of a bar chart for historical revenue concentration and a floating bar chart (range) for analyst revenue estimates.", "elementsJson": null, "confidence": 0.95, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 21:01:14.521+00", "seconds": 4.694, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-622c-750b-8b9d-0fffb58e3a0f/7", "deck": "/decks/019dd923-622c-750b-8b9d-0fffb58e3a0f", "deckAnchor": "/decks/019dd923-622c-750b-8b9d-0fffb58e3a0f#slide-7", "deckJson": "/decks/019dd923-622c-750b-8b9d-0fffb58e3a0f.json" }, "components": [ { "bbox": { "h": 0.25, "w": 0.78, "x": 0.11, "y": 0.12 }, "kind": "chart", "text": "Historical revenue concentration of blockbuster drugs", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 21:01:14.521+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5d166c6d-faa4-4841-895f-ff4e68c6d5bd", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.78, "x": 0.11, "y": 0.65 }, "kind": "chart", "text": "Analyst revenue projections range for pipeline products", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 21:01:14.521+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c843354b-36a1-4e5f-9d55-115210e1cda4", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.78, "x": 0.11, "y": 0.42 }, "kind": "paragraph", "text": "Based on our analysis of the Celgene pipeline, we believe that Bristol-Myers' projections are extremely optimistic, especially given the most recent developments. Based on our conversations with Bristol-Myers management, we believe that the Company is attributing 60% of 2028 pipeline revenues to five near-term product launch opportunities (i.e. luspatercept, JCAR017, bb2121, fedratinib, and ozanimod), with the remainder of revenues generated by ~20 earlier-stage assets, of which greater than 60% of indications are still in Phase I development. Not surprisingly, sell-side analyst revenue projections for each of the five near-term products reveal wildly differing outlooks. In fact, as shown below, there is a $7.3 billion difference between the minimum and maximum cumulative 2028 revenue estimates for these five products.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 21:01:14.521+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "04de2ef0-7984-4c02-bbff-2e9d45df305a", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.78, "x": 0.11, "y": 0.38 }, "kind": "source-note", "text": "Source: Company Filings. (1) % revenues for SINGULAIR, LIPITOR, CRESTOR, CYMBALTA, PLAVIX, and REVLIMID as of 2011, 2010, 2015, 2013, 2011, and 2018, respectively.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 21:01:14.521+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cd9765a6-486a-4c93-8d5e-28dd579c4fb2", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.2, "x": 0.11, "y": 0.89 }, "kind": "source-note", "text": "Source: Wall Street Estimates.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 21:01:14.521+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f7fa4462-740d-479a-adf9-546343380af5", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.78, "x": 0.11, "y": 0.61 }, "kind": "title", "text": "2028 Wall Street Est. for Near-Term Launch Pipeline Product Revenue", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 21:01:14.521+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "635adbb3-0aae-4690-9961-798f5a2ed9d7", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.78, "x": 0.11, "y": 0.09 }, "kind": "title", "text": "Select Blockbuster Drugs - % Revenue Contribution Prior to Loss-of-Exclusivity(1)", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 21:01:14.521+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9cde3f7b-a8f9-40d9-b15f-cfa999e0074c", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "0624b94c-427f-4d55-adc7-f78526c2de81", "evidence": "Comparing historical drug revenue concentration with future pipeline revenue uncertainty.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 21:01:14.521+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 7, "frameworkName": "comparison_frame" } ], "arcBeats": [ { "to": 9, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 7, "name": "Agitate", "beatId": "b2d08d86-8e4d-47b4-8dc5-26870b4df100", "matchId": "b3a3f81d-4c4c-427b-9370-7740b99af9bf", "beatType": { "name": "Agitate (Make it worse)", "slug": "problem-agitate-solution-agitate-make-it-worse", "status": "active", "canonId": "019dd9b8-0f5a-71dd-bae7-8fadb0d09456", "version": 1, "description": null }, "evidence": "The document then questions the company's R&D productivity", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Development", "slug": "development", "status": "active", "canonId": "019dd9b8-0332-7008-b3aa-11b0840a57b1", "version": 1, "description": "The middle stretch in arcs that have one. Often where length problems creep in." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 9, "from": 2, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "9478efc2-9f01-4b02-a15d-2d6af84ca74a", "evidence": "The document highlights the underperformance and questions R&D productivity, implying a cost of inaction", "position": 0, "objective": "to highlight the cost of not improving R&D productivity", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:03:56.892514+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 8, "type": "tension", "title": "Uses a stacked area chart to show revenue projections and pull-quotes to highlight past management over-promising.", "function": "expose_contradiction", "rawType": "expose_contradiction", "block": null, "metadata": { "slideType": "expose_contradiction", "slideTypeCanon": { "name": "Expose contradiction", "slug": "expose_contradiction", "status": "active", "canonId": "019de52d-124c-75aa-984a-0a3d0d8fc8df", "version": 1, "description": null }, "function": "expose_contradiction", "functionCanon": { "name": "Expose contradiction", "slug": "expose_contradiction", "status": "active", "canonId": "019de52d-171f-776f-887c-73edaff4cf9c", "version": 1, "description": null }, "density": "dense", "densityScore": 56, "componentCount": 6, "textChars": 947, "nDataPoints": 5, "notes": "Uses a stacked area chart to show revenue projections and pull-quotes to highlight past management over-promising.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 21:01:14.064+00", "seconds": 4.058, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-622c-750b-8b9d-0fffb58e3a0f/8", "deck": "/decks/019dd923-622c-750b-8b9d-0fffb58e3a0f", "deckAnchor": "/decks/019dd923-622c-750b-8b9d-0fffb58e3a0f#slide-8", "deckJson": "/decks/019dd923-622c-750b-8b9d-0fffb58e3a0f.json" }, "components": [ { "bbox": { "h": 0.23, "w": 0.63, "x": 0.118, "y": 0.195 }, "kind": "chart", "text": "Stacked area chart showing revenue projections for five products from 2019 to 2028.", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Stacked area chart", "slug": "area-stacked", "status": "active", "canonId": "019de52c-ffb1-75fa-a614-76782f418cf1", "version": 1, "description": null }, "framework": null }, "subkind": "area-stacked", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 21:01:14.064+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5d093d6b-87f3-4716-b25c-b8e9f2f4f79e", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.764, "x": 0.118, "y": 0.478 }, "kind": "paragraph", "text": "Based on Celgene’s most recent track record of overpromising and under-delivering on highly-touted pipeline products – specifically, the termination of GED-0301 and the refusal-to-file (“RTF”) for ozanimod – we question whether management’s projections are sufficiently conservative.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 21:01:14.064+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "96526e09-9593-4e16-924d-268316f0a0f6", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.764, "x": 0.118, "y": 0.75 }, "kind": "quote", "text": "1-month before receiving refusal-to-file notice from FDA on ozanimod: 'Focusing on execution, the NDA for ozanimod in RMS was submitted... We are currently building out a strong neuro-inflammation team to execute a launch...'", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": null, "subkind": { "name": "Testimonial", "slug": "testimonial", "status": "active", "canonId": "019de52c-fc21-71b6-9ac3-8266a64945e8", "version": 1, "description": null }, "framework": null }, "subkind": "testimonial", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 21:01:14.064+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "298d79e2-7e2c-4489-96d3-e6bca0e3f696", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.764, "x": 0.118, "y": 0.6 }, "kind": "quote", "text": "7-months before termination of GED-0301: 'And then you have ozanimod, GED-0301... GED-0301 for Crohn’s disease could be transformational as well. In our opinion, it’s probably a multi-billion dollar asset as well.'", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": null, "subkind": { "name": "Testimonial", "slug": "testimonial", "status": "active", "canonId": "019de52c-fc21-71b6-9ac3-8266a64945e8", "version": 1, "description": null }, "framework": null }, "subkind": "testimonial", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 21:01:14.064+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "86fa1df9-519d-4c01-8d3a-60458c8eacd3", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.764, "x": 0.118, "y": 0.565 }, "kind": "title", "text": "Select Celgene Management Commentary on GED-0301 and ozanimod", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 21:01:14.064+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "004963a1-7897-4b8d-bf3f-f55e7a374740", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.764, "x": 0.118, "y": 0.168 }, "kind": "title", "text": "'19 – '28 Wall Street Maximum Est. for Celgene Near-Term Launch Pipeline Products", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 21:01:14.064+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5a417686-b2b9-484b-abe0-7d85fd10ac96", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "46bb7d83-e9b0-4059-9f1d-1bf78dca2ac3", "evidence": "Contrasts past management quotes with subsequent negative outcomes (termination/RTF).", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 21:01:14.064+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 8, "frameworkName": "ceo-quote-contradiction" } ], "arcBeats": [ { "to": 9, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 7, "name": "Agitate", "beatId": "b2d08d86-8e4d-47b4-8dc5-26870b4df100", "matchId": "b3a3f81d-4c4c-427b-9370-7740b99af9bf", "beatType": { "name": "Agitate (Make it worse)", "slug": "problem-agitate-solution-agitate-make-it-worse", "status": "active", "canonId": "019dd9b8-0f5a-71dd-bae7-8fadb0d09456", "version": 1, "description": null }, "evidence": "The document then questions the company's R&D productivity", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Development", "slug": "development", "status": "active", "canonId": "019dd9b8-0332-7008-b3aa-11b0840a57b1", "version": 1, "description": "The middle stretch in arcs that have one. Often where length problems creep in." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 9, "from": 2, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "9478efc2-9f01-4b02-a15d-2d6af84ca74a", "evidence": "The document highlights the underperformance and questions R&D productivity, implying a cost of inaction", "position": 0, "objective": "to highlight the cost of not improving R&D productivity", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:03:56.892514+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 9, "type": "tension", "title": "The slide uses a combination of a line chart to show financial decline and a timeline to show management's shifting narrative.", "function": "expose_contradiction", "rawType": "expose_contradiction", "block": null, "metadata": { "slideType": "expose_contradiction", "slideTypeCanon": { "name": "Expose contradiction", "slug": "expose_contradiction", "status": "active", "canonId": "019de52d-124c-75aa-984a-0a3d0d8fc8df", "version": 1, "description": null }, "function": "expose_contradiction", "functionCanon": { "name": "Expose contradiction", "slug": "expose_contradiction", "status": "active", "canonId": "019de52d-171f-776f-887c-73edaff4cf9c", "version": 1, "description": null }, "density": "dense", "densityScore": 65, "componentCount": 8, "textChars": 812, "nDataPoints": 2, "notes": "The slide uses a combination of a line chart to show financial decline and a timeline to show management's shifting narrative.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 21:01:17.859+00", "seconds": 4.769, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-622c-750b-8b9d-0fffb58e3a0f/9", "deck": "/decks/019dd923-622c-750b-8b9d-0fffb58e3a0f", "deckAnchor": "/decks/019dd923-622c-750b-8b9d-0fffb58e3a0f#slide-9", "deckJson": "/decks/019dd923-622c-750b-8b9d-0fffb58e3a0f.json" }, "components": [ { "bbox": { "h": 0.215, "w": 0.746, "x": 0.127, "y": 0.268 }, "kind": "chart", "text": "Line chart showing revenue estimates for KYMIRAH and YESCARTA from Feb-14 to Aug-18.", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 21:01:17.859+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bb9b31b9-0c5c-4828-855b-616673ee94e4", "parentComponentId": null }, { "bbox": { "h": 0.255, "w": 0.764, "x": 0.118, "y": 0.635 }, "kind": "framework", "text": "Timeline of management quotes from Jan 2018 to Jan 2019.", "attrs": null, "canon": { "kind": { "name": "Framework", "slug": "framework", "status": "active", "canonId": "019de52c-fa18-77c6-b10a-ccb8277ac0fa", "version": 1, "description": "Named conceptual framework instance." }, "tool": null, "subkind": { "name": "Framework instance", "slug": "instance", "status": "active", "canonId": "019de52d-05a2-72af-be0b-7edc60708a03", "version": 1, "description": null }, "framework": null }, "subkind": "instance", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 21:01:17.859+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f480f4e8-0662-4b9a-827f-2883874e8ec3", "parentComponentId": null }, { "bbox": { "h": 0.043, "w": 0.764, "x": 0.118, "y": 0.537 }, "kind": "paragraph", "text": "While Celgene management has argued that JCAR017 and bb2121 have demonstrated a superior safety profile in early-stage trials, their recent commentary on timelines for approval has become more measured.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 21:01:17.859+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "109cb393-dffa-4fc3-8ab6-1fe23f0c0ddc", "parentComponentId": null }, { "bbox": { "h": 0.065, "w": 0.764, "x": 0.118, "y": 0.111 }, "kind": "paragraph", "text": "For example, Chimeric Antigen Receptor T-cell (“CAR-T”) therapies, which account for two of the five near-term product launch opportunities, are prime examples of a category where sell-side revenue estimates have massively declined since the drugs have come to market.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 21:01:17.859+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "657bf289-4c9f-47bf-af0c-f1b7d97fcd89", "parentComponentId": null }, { "bbox": { "h": 0.012, "w": 0.225, "x": 0.118, "y": 0.908 }, "kind": "source-note", "text": "Source: Company Filings and Transcripts.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 21:01:17.859+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "839fd3fe-c7df-47d4-9308-24660dcb563c", "parentComponentId": null }, { "bbox": { "h": 0.012, "w": 0.225, "x": 0.118, "y": 0.506 }, "kind": "source-note", "text": "Source: Wall Street Estimates, Bloomberg.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 21:01:17.859+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d537d393-1192-4d96-bd4d-f89c35970e5c", "parentComponentId": null }, { "bbox": { "h": 0.022, "w": 0.764, "x": 0.118, "y": 0.607 }, "kind": "title", "text": "Timeline of Celgene Management Commentary on JCAR017 (i.e. liso-cel)", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 21:01:17.859+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "04efeded-a22b-4556-a95b-b7f7e7d4b18e", "parentComponentId": null }, { "bbox": { "h": 0.022, "w": 0.764, "x": 0.118, "y": 0.231 }, "kind": "title", "text": "2022 Wall Street Revenue Estimates For Approved CAR-T", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 21:01:17.859+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e17eb729-cc42-49ce-baf2-d67204a39e2c", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "8ed2b16b-5c76-4fde-ab06-babd12451c0b", "evidence": "Contrasting past optimistic quotes with later, more measured statements.", "framework": null, "confidence": 0.95, "extraction": { "at": "2026-05-02 21:01:17.859+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 9, "frameworkName": "ceo-quote-contradiction" }, { "matchId": "71b7bb2e-d227-4dcb-9338-c047141878a9", "evidence": "Visual representation of management quotes over time.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 21:01:17.859+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 9, "frameworkName": "timeline" } ], "arcBeats": [ { "to": 9, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 7, "name": "Agitate", "beatId": "b2d08d86-8e4d-47b4-8dc5-26870b4df100", "matchId": "b3a3f81d-4c4c-427b-9370-7740b99af9bf", "beatType": { "name": "Agitate (Make it worse)", "slug": "problem-agitate-solution-agitate-make-it-worse", "status": "active", "canonId": "019dd9b8-0f5a-71dd-bae7-8fadb0d09456", "version": 1, "description": null }, "evidence": "The document then questions the company's R&D productivity", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Development", "slug": "development", "status": "active", "canonId": "019dd9b8-0332-7008-b3aa-11b0840a57b1", "version": 1, "description": "The middle stretch in arcs that have one. Often where length problems creep in." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 9, "from": 2, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "9478efc2-9f01-4b02-a15d-2d6af84ca74a", "evidence": "The document highlights the underperformance and questions R&D productivity, implying a cost of inaction", "position": 0, "objective": "to highlight the cost of not improving R&D productivity", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:03:56.892514+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 10, "type": "setup", "block": null, "metadata": { "slideType": null, "slideTypeCanon": null, "function": null, "functionCanon": null, "density": null, "densityScore": null, "componentCount": null, "textChars": null, "nDataPoints": null, "notes": null, "elementsJson": null, "confidence": null, "extraction": { "model": null, "runId": null, "at": null, "seconds": null, "promptVersion": null } }, "links": { "slide": "/slides/019dd923-622c-750b-8b9d-0fffb58e3a0f/10", "deck": "/decks/019dd923-622c-750b-8b9d-0fffb58e3a0f", "deckAnchor": "/decks/019dd923-622c-750b-8b9d-0fffb58e3a0f#slide-10", "deckJson": "/decks/019dd923-622c-750b-8b9d-0fffb58e3a0f.json" }, "components": [], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 11, "type": "setup", "block": null, "metadata": { "slideType": null, "slideTypeCanon": null, "function": null, "functionCanon": null, "density": null, "densityScore": null, "componentCount": null, "textChars": null, "nDataPoints": null, "notes": null, "elementsJson": null, "confidence": null, "extraction": { "model": null, "runId": null, "at": null, "seconds": null, "promptVersion": null } }, "links": { "slide": "/slides/019dd923-622c-750b-8b9d-0fffb58e3a0f/11", "deck": "/decks/019dd923-622c-750b-8b9d-0fffb58e3a0f", "deckAnchor": "/decks/019dd923-622c-750b-8b9d-0fffb58e3a0f#slide-11", "deckJson": "/decks/019dd923-622c-750b-8b9d-0fffb58e3a0f.json" }, "components": [], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 12, "type": "setup", "block": null, "metadata": { "slideType": null, "slideTypeCanon": null, "function": null, "functionCanon": null, "density": null, "densityScore": null, "componentCount": null, "textChars": null, "nDataPoints": null, "notes": null, "elementsJson": null, "confidence": null, "extraction": { "model": null, "runId": null, "at": null, "seconds": null, "promptVersion": null } }, "links": { "slide": "/slides/019dd923-622c-750b-8b9d-0fffb58e3a0f/12", "deck": "/decks/019dd923-622c-750b-8b9d-0fffb58e3a0f", "deckAnchor": "/decks/019dd923-622c-750b-8b9d-0fffb58e3a0f#slide-12", "deckJson": "/decks/019dd923-622c-750b-8b9d-0fffb58e3a0f.json" }, "components": [], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 13, "type": "tension", "title": "Uses a 'CEO Quote vs. Reality' structure to highlight management failure.", "function": "expose_contradiction", "rawType": "expose_contradiction", "block": null, "metadata": { "slideType": "expose_contradiction", "slideTypeCanon": { "name": "Expose contradiction", "slug": "expose_contradiction", "status": "active", "canonId": "019de52d-124c-75aa-984a-0a3d0d8fc8df", "version": 1, "description": null }, "function": "expose_contradiction", "functionCanon": { "name": "Expose contradiction", "slug": "expose_contradiction", "status": "active", "canonId": "019de52d-171f-776f-887c-73edaff4cf9c", "version": 1, "description": null }, "density": "dense", "densityScore": 50, "componentCount": 6, "textChars": 728, "nDataPoints": 3, "notes": "Uses a 'CEO Quote vs. Reality' structure to highlight management failure.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 21:01:17.731+00", "seconds": 3.291, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-622c-750b-8b9d-0fffb58e3a0f/13", "deck": "/decks/019dd923-622c-750b-8b9d-0fffb58e3a0f", "deckAnchor": "/decks/019dd923-622c-750b-8b9d-0fffb58e3a0f#slide-13", "deckJson": "/decks/019dd923-622c-750b-8b9d-0fffb58e3a0f.json" }, "components": [ { "bbox": { "h": 0.285, "w": 0.746, "x": 0.127, "y": 0.461 }, "kind": "chart", "text": "5-Year Share Price Performance", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 21:01:17.731+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7975459d-9b62-420f-a9c0-a5f5929fc65a", "parentComponentId": null }, { "bbox": { "h": 0.045, "w": 0.764, "x": 0.118, "y": 0.391 }, "kind": "paragraph", "text": "Unfortunately, R&D failures continue to plague the Company and have destroyed significant shareholder value in the process. Over the past five years, the Company has underperformed peers and the broader market index by approximately 40%.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 21:01:17.731+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6e4c67b2-0d2b-499c-85de-b0048b4660e0", "parentComponentId": null }, { "bbox": { "h": 0.035, "w": 0.764, "x": 0.118, "y": 0.824 }, "kind": "paragraph", "text": "The past year has been particularly painful for Bristol-Myers shareholders, as key clinical trials have failed to show the desired results and the Company’s future growth trajectory has been called into question.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 21:01:17.731+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8fbc20bc-f7c1-481f-8459-d3eb40fc24d0", "parentComponentId": null }, { "bbox": { "h": 0.085, "w": 0.764, "x": 0.118, "y": 0.252 }, "kind": "quote", "text": "I'm also excited by the progress with our diversified pipeline... we are executing very well...", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": null, "subkind": { "name": "Pull quote", "slug": "pull-quote", "status": "active", "canonId": "019de52c-fbf9-76fe-97e1-a0b7540445c9", "version": 1, "description": null }, "framework": null }, "subkind": "pull-quote", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 21:01:17.731+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0b7147be-c6c0-4259-b357-b5878d8db07b", "parentComponentId": null }, { "bbox": { "h": 0.085, "w": 0.764, "x": 0.118, "y": 0.133 }, "kind": "quote", "text": "Finally, our emerging pipeline across all therapeutic areas is one of the most promising in our history...", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": null, "subkind": { "name": "Pull quote", "slug": "pull-quote", "status": "active", "canonId": "019de52c-fbf9-76fe-97e1-a0b7540445c9", "version": 1, "description": null }, "framework": null }, "subkind": "pull-quote", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 21:01:17.731+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2d9bd439-5bac-4ea9-acfe-ba0d6a2bbe6b", "parentComponentId": null }, { "bbox": { "h": 0.028, "w": 0.764, "x": 0.118, "y": 0.092 }, "kind": "title", "text": "Select Management Commentary on R&D Productivity", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 21:01:17.731+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "866d5117-24dd-410b-8981-5e20abab7dfc", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "0eb9bb6c-81ee-483a-8abf-77083f7fd13b", "evidence": "Contrasting optimistic CEO quotes with negative stock performance data.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 21:01:17.731+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 13, "frameworkName": "ceo-quote-contradiction" } ], "arcBeats": [ { "to": 13, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 13, "name": "Solution", "beatId": "69150cef-b68a-4ac9-9ada-bbc434fbe962", "matchId": "b3a3f81d-4c4c-427b-9370-7740b99af9bf", "beatType": { "name": "Solution (Provide relief)", "slug": "problem-agitate-solution-solution-provide-relief", "status": "active", "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd", "version": 1, "description": null }, "evidence": "The document provides a solution to improve R&D productivity", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 13, "from": 13, "loop": { "name": "51_voice_of_customer", "slug": "51-voice-of-customer", "status": "active", "bestFor": "Product strategy, customer experience, market research", "canonId": "019dd956-7aaf-750b-950b-af0df38f5266", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "What Customers Say (Verbatim) -> The Pattern Across Voices -> The Insight -> The Response", "description": "Let customer quotes and feedback drive the narrative and validate the insight", "familyLabel": null }, "matchId": "996cc727-a228-47d1-8c7f-e4954377a0d3", "evidence": "The document provides select management commentary on R&D productivity", "position": 1, "objective": "to provide a solution that addresses shareholder concerns", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:03:56.928365+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 14, "type": "setup", "block": null, "metadata": { "slideType": null, "slideTypeCanon": null, "function": null, "functionCanon": null, "density": null, "densityScore": null, "componentCount": null, "textChars": null, "nDataPoints": null, "notes": null, "elementsJson": null, "confidence": null, "extraction": { "model": null, "runId": null, "at": null, "seconds": null, "promptVersion": null } }, "links": { "slide": "/slides/019dd923-622c-750b-8b9d-0fffb58e3a0f/14", "deck": "/decks/019dd923-622c-750b-8b9d-0fffb58e3a0f", "deckAnchor": "/decks/019dd923-622c-750b-8b9d-0fffb58e3a0f#slide-14", "deckJson": "/decks/019dd923-622c-750b-8b9d-0fffb58e3a0f.json" }, "components": [], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 15, "type": "setup", "block": null, "metadata": { "slideType": null, "slideTypeCanon": null, "function": null, "functionCanon": null, "density": null, "densityScore": null, "componentCount": null, "textChars": null, "nDataPoints": null, "notes": null, "elementsJson": null, "confidence": null, "extraction": { "model": null, "runId": null, "at": null, "seconds": null, "promptVersion": null } }, "links": { "slide": "/slides/019dd923-622c-750b-8b9d-0fffb58e3a0f/15", "deck": "/decks/019dd923-622c-750b-8b9d-0fffb58e3a0f", "deckAnchor": "/decks/019dd923-622c-750b-8b9d-0fffb58e3a0f#slide-15", "deckJson": "/decks/019dd923-622c-750b-8b9d-0fffb58e3a0f.json" }, "components": [], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 16, "type": "setup", "block": null, "metadata": { "slideType": null, "slideTypeCanon": null, "function": null, "functionCanon": null, "density": null, "densityScore": null, "componentCount": null, "textChars": null, "nDataPoints": null, "notes": null, "elementsJson": null, "confidence": null, "extraction": { "model": null, "runId": null, "at": null, "seconds": null, "promptVersion": null } }, "links": { "slide": "/slides/019dd923-622c-750b-8b9d-0fffb58e3a0f/16", "deck": "/decks/019dd923-622c-750b-8b9d-0fffb58e3a0f", "deckAnchor": "/decks/019dd923-622c-750b-8b9d-0fffb58e3a0f#slide-16", "deckJson": "/decks/019dd923-622c-750b-8b9d-0fffb58e3a0f.json" }, "components": [], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true } ], "arcBeats": [ { "from": 2, "to": 2, "label": "Problem", "description": "The document starts by highlighting the underperformance of Bristol-Myers Share Price" }, { "from": 7, "to": 9, "label": "Agitate", "description": "The document then questions the company's R&D productivity" }, { "from": 13, "to": 13, "label": "Solution", "description": "The document provides a solution to improve R&D productivity" } ], "loops": [ { "from": 2, "to": 9, "label": "Cost Of Inaction", "description": "to highlight the cost of not improving R&D productivity" }, { "from": 13, "to": 13, "label": "Voice Of Customer", "description": "to provide a solution that addresses shareholder concerns" } ] }